Dare Bioscience, Inc. quarterly report, Q3 FY2017

Daré Bioscience, Inc. — Q3 2017 Form 10-Q

Reporting period: Quarter and nine months ended September 30, 2017. The filing was signed November 13, 2017. Daré is a pre-commercial women’s reproductive health company; its lead candidate is Ovaprene, a non-hormonal contraceptive intravaginal ring. It reported no revenue.

Financial position and results

MetricQ3 / September 30, 2017Comparable period / prior balance
RevenueNone reportedNone reported
Operating expenses$1.33 million for the quarter; $2.04 million for nine monthsQuarter: $5,963; nine months: $441,949
Net loss$1.63 million for the quarter; $2.37 million for nine monthsQuarter: $16,105; nine months: $472,154
Cash and cash equivalents$8.53 million$44,614 at December 31, 2016
Operating cash flow$(1.58) million for nine months$(205,347) for nine months ended September 30, 2016
Total assets / goodwill$23.27 million / $12.88 millionTotal assets: $44,614 at December 31, 2016
Total liabilities$839,531$755,235 at December 31, 2016
Accumulated deficit$3.10 million$727,835 at December 31, 2016

Margins are not meaningful because the company had no revenue. The September 30 balance sheet showed $10.38 million of current assets and $839,374 of current liabilities. Convertible notes were no longer outstanding at quarter-end: they converted into equity immediately before the July transaction.

Material changes and unusual items

  • On July 19, 2017, the former private Daré was acquired by Cerulean Pharma in a stock transaction; former private Daré holders received approximately 51% of the combined company. Cerulean then changed its name to Daré Bioscience. The transaction was accounted for as a reverse merger, so pre-transaction and post-transaction comparisons are not directly comparable.
  • Cerulean sold its Dynamic Tumor Targeting platform to Novartis for $6.0 million. The filing reports $9.92 million of cash acquired through the transaction in investing cash flows.
  • General and administrative expense included $963,380 of transaction costs for the nine-month period. Interest expense included a $316,804 charge for the beneficial conversion feature of the notes.
  • Research and development spending was primarily for Ovaprene. It rose to $312,169 for the first nine months of 2017 from $72,666 in the comparable period; 2016 also included $250,000 of license expense.
  • A 1-for-10 reverse stock split took effect July 20, 2017. The filing reports 6,047,161 common shares outstanding as of November 6, 2017.

Outlook, commitments, and risks

  • Management estimated existing resources would fund planned operations for approximately two years and allow Daré to commence and complete an Ovaprene postcoital clinical trial. This estimate depends on assumptions that may prove incorrect; management said additional financing would be needed for further development, including a pivotal contraceptive study, and future candidates.
  • The company expects losses and research and development expenses to increase. It has not generated revenue and may seek capital through equity or debt offerings, grants, collaborations, or strategic alliances; financing may not be available on acceptable terms and equity financing could dilute shareholders.
  • The ADVA-Tec Ovaprene license carries up to $14.6 million in development and regulatory milestone payments, up to $20.0 million in sales milestone payments, royalties of 1%–10% of specified net sales, and minimum development spending totaling $5.0 million over the first three years. Failure to meet specified obligations could permit termination of the license.
  • Key risks include clinical-trial failure or delay, regulatory approval uncertainty, dependence on external partners and manufacturers, intellectual-property and licensing risks, competition, and the need to raise additional capital. The company said there had been no material changes to the risk factors disclosed in its June 30, 2017 Form 10-Q.
  • No material pending litigation was reported. Management concluded disclosure controls were effective at a reasonable assurance level; no material change in internal control over financial reporting was reported.

Investor verification points

  • Track cash burn against management’s approximate two-year runway estimate and the timing and terms of future financing.
  • Verify progress, trial design, enrollment, and regulatory milestones for Ovaprene, including whether the postcoital study is completed as planned.
  • Review the ADVA-Tec license’s minimum-spending requirements, milestone obligations, royalty terms, and termination provisions.
  • Assess the reverse-merger accounting, final purchase-price allocation, goodwill balance, and any subsequent impairment indicators.
  • Confirm that comparable-period analysis accounts for the July 2017 transaction and reverse stock split, and distinguish recurring operating costs from transaction-related and non-cash charges.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.